Overview

Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis

Status:
Completed

Trial end date:
2007-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the ability of once-daily (QD) treatment with dexlansoprazole modified release (MR) 30 mg and 60 mg or placebo in maintaining healing of erosive esophagitis (EE).

Phase:

Phase 3

Details

Lead Sponsor:

Takeda

Treatments:

Dexlansoprazole
Lansoprazole